ASH: With high tumor response, AstraZeneca spinout Dizal explores FDA path and US partner for PTCL drug

Just as the FDA revisits two accelerated approvals in peripheral T cell lymphoma (PTCL), AstraZeneca spinout Dizal Pharmaceutical is charting its own path for a potential conditional nod in the blood cancer.

The Chinese biotech has phase 2 tumor response data for its JAK1 inhibitor golidocitinib that, as CEO Xiaolin Zhang, Ph.D., pointed out, look better than readouts from existing therapies in previously treated PTCL.